E353: Why Biotech Is Struggling in Today’s Market (and the Future of Healthcare)

Biotech investment is under pressure due to declining revenue potential from drug pricing reforms like the Inflation Reduction Act, which has led to a 30% NPV hit for drugs and a 70% drop in small molecule investment. Meanwhile, China now accounts for 60% of new drug starts, creating competitive pressure that forces U.S. innovation toward AI-driven platforms and new business models. Despite rising M&A activity and deal values, the combination of a lower revenue ceiling and higher development costs is compressing returns and shifting capital toward higher-upside sectors.

Understand how U.S. policy, global competition from China, and AI are reshaping the economic viability and future of biotech innovation.

1. 01The Inflation Reduction Act has significantly reduced the net present value of biotech drugs by enabling mandatory price negotiations, disproportionately impacting small molecule developers with a 70% decline in new starts.
2. 02China is now the dominant source of new drug development, accounting for 60% of new drug starts and forcing U.S. biotech to innovate through AI and efficiency to remain competitive.
3. 03Investor appetite is shifting away from traditional biotech due to compressed multiples and uncertain long-term returns, despite strong scientific missions, in favor of sectors with higher growth ceilings.